A Phase 2 interventional study of BCS+inactive and BCS+active in Chronic Cough (CC), Refractory Chronic Cough and Unexplained Chronic Cough, sponsored by University of Montana. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by University of Montana · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Chronic Cough with a site in United States — 9 open to participants now, 10 under way, none of them phase 3. Chronic Cough · United States.
Among the 44 studies in Chronic Cough with a site in United States, this one is the 12th largest by planned enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2026, is one of 16 in phase 2, and was the 42nd registered.
142 studies on the registry are indexed under Chronic Cough; 38 are open to participants now.
Browse Chronic Cough studies →9 of the 44 studies in Chronic Cough with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18–80
Hyfe Inc · Sites in United States
Ages 21+
Medical University of South Carolina · Sites in United States
Ages 18+
University of Montana · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Chronic Cough studies recruiting now, 10 (33%) set no upper age limit and 12 (40%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 135 is above the median of 60 across 104 interventional studies indexed under Chronic Cough.
Median enrollment 50 across the 37 interventional studies, 35 across the 7 observational. Of the 33 that completed or were terminated, 16 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 44 have an industry lead sponsor. The 10 most frequent:
University of Montana is the lead sponsor of 28 studies on the registry; 11 are open to participants now.
University of Montana has 5 studies filed under Chronic Cough — fewer than ten, so there is no comparison to draw.
3 of the studies in Chronic Cough with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05110144Mayo ClinicEfficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough | 2026-12 |
| NCT05273190University of MinnesotaStimulation of the Larynx to Treat Unexplained Chronic Cough | 2027-06-01 |
| NCT06634823Medical University of South CarolinaEfficacy of Intramuscular Steroid Injection for Chronic Cough. | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 44 studies in Chronic Cough with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is testing new ways to help people who have chronic cough that has not improved with typical treatments. One approach is called behavioral cough suppression (BCS) therapy, which teaches people techniques to stop themselves from coughing. Another approach uses a natural substance thought to help reduce the body's sensitivity to cough triggers.
In this study, we will test two treatments and include one no-treatment control group. The control group will undergo baseline testing, cough monitoring, and an fMRI brain scan and will be offered BCS at end of study participation.
The two treatments include:
The investigators will enroll 135 adults with refractory chronic cough (RCC). 100 participants who qualify and are willing and able to complete 14 study visits in the clinic and two online study visits will be randomly assigned to one of the two treatments. The no-treatment control group (n=35) will be recruited from adults with RCC who are willing to complete baseline testing and fMRI but are not able or willing to attend 14 study clinic visits. These participants will not be randomized.
The investigators want to find out how these treatments affect:
The investigators believe both treatments will reduce sensitivity to cough stimulants, reduce cough severity, and improve quality of life, but BCS+active inhaled treatment will work better than BCS+inactive inhaled treatment.
Refractory chronic cough (RCC) is a persistent and costly condition that is difficult to treat, often persisting despite appropriate treatment of underlying causes. While behavioral cough suppression (BCS) therapy has shown effectiveness in reducing cough frequency and improving quality of life in controlled studies, it remains underutilized, and the mechanisms by which it works are not well understood.
This multi-site randomized controlled trial will investigate the effects and mechanisms of BCS therapy with and without the addition of an inhaled substance designed to enhance the effect of BCS treatment. The active inhaled substance used in the study has demonstrated desensitization effects on sensory pathways in conditions such as chronic rhinitis and pain syndromes, suggesting potential utility in modulating cough-related neural pathways. Inhalation of this substance has been shown to be safe across multiple studies.
The investigators will recruit 135 participants diagnosed with RCC. 100 participants will be randomized into one of two treatment arms -- BCS combined with an active inhaled substance, and BCS combined with an inactive inhalant. A non-randomized no-treatment control group (n=35) will be included to provide a control comparison to fMRI.
Participants in the treatment arms will undergo 12 treatment sessions over several weeks. The study will evaluate both behavioral and neural markers of treatment response. Primary outcome measures will include:
The following patient-report outcome measures (PROMS) will be included as secondary outcomes:
Ambulatory cough frequency monitoring will also be included as a secondary outcome. This data will be collected with the CoughMonitor smartwatch by Hyfe, Inc.
The investigators hypothesize that both treatments will lead to desensitization of cough sensitivity (i.e., increase in C5). We further hypothesize that the combination of BCS+active inhaled treatment will provide the greatest therapeutic benefit on all outcome measures due to simultaneous peripheral desensitization and central sensory-motor modulation. Regarding fMRI, we hypothesize that both treatments will result in increased activity in areas responsible for motor inhibition (e.g., prefrontal cortex).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible to participate, participants must meet the following criteria:
If you a potential participant has asthma, the following criteria must be met:
EXCLUSION CRITERIA
Any of the following will be grounds for exclusion from the study:
Asthma criteria - participant is deemed ineligible if screened for one or more of the following:
Excluded concomitant medications:
The following additional exclusion criteria will apply to participants who will undergo fMRI:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive behavioral cough suppression therapy (BCST) combined with an inactive inhaled substance.
Behavioral: BCS+inactive
Participants receive behavioral cough suppression (BCS) therapy combined with inhaled drug designed to enhance BCS therapy
Combination Product: BCS+active
Participants will undergo assessments without treatment
Behavioral cough suppression therapy plus inactive inhaled drug. Treatment given twice per week for 12 sessions.
Behavioral cough suppression therapy combined with inhaled natural substance known to desensitize sensory nerves. Treatment given twice per week for 12 sessions.
Cough threshold sensory testing (CTT)
Measure of cough sensitivity using progressive doses of inhaled vaporized citric acid. The dose causing 5 or more coughs (C5) is the endpoint.
Time frame: From enrollment to 4 weeks following enrollment
Cough suppression threshold difference (CS Thresh Diff)
Measure of cough suppression ability. The participant first completes cough suppression threshold testing which involves inhalation of progressive doses of citric acid while actively trying to suppress cough. The dose causing 5 or more coughs when trying to not cough (CS5) is the endpoint. CS Thresh Diff is the difference between CS5 and C5.
Time frame: From enrollment to 4 weeks following enrollment
Urge-to-Cough Sensory Motor Threshold Difference (UTC S-M Thresh Diff)
A measure of the relationship between sensation of UTC and motor action of coughing. The measure is determined by calculating the difference between first UTC felt during cough threshold testing (Cu) and UTC at the dose of citric acid that causes 2 or more coughs (C2) (i.e., UTC at C2 - UTC at Cu).
Time frame: From enrollment to 4 weeks following enrollment
Blood oxygen level dependent neural responses (BOLD)
Whole-brain fMRI performed during inhalation of capsaicin to trigger urge-to-cough. (NOTE: this measure is only required for those enrolling at Univ. of Colorado)
Time frame: 4 weeks following enrollment BCS+CAP and BCS+Sham participants; enrollment to 1 week post-enrollment for the fMRI control group
Leicester Cough Questionnaire (LCQ)
19-item patient-report outcome measure related to the impact of cough on quality of life
Time frame: From enrollment to 19 weeks following enrollment
Cough frequency
Ambulatory cough frequency monitoring with a specialized smartwatch, which is worn for 5 days before treatment and 5 days following treatment
Time frame: From enrollment to 11 weeks following enrollment
Newcastle Laryngeal Hypersensitivity Questionnaire (NLHQ)
The NLHQ consists of 14 questions assessing laryngeal paresthesia (i.e., abnormal sensory symptoms) commonly seen in RCC. A lower score indicates greater paresthesia.
Time frame: From enrollment to 19 weeks following enrollment
Voice Handicap Index - 10 (VHI-10)
The VHI-10 assesses the functional impact of dysphonia on life, which is often seen in patients with RCC. The higher the score, the greater the impact of dysphonia on life.
Time frame: From enrollment to 19 weeks following enrollment
Multidimensional Assessment of Interoceptive Awareness (MAIA-2)
The MAIA-2 has 14 questions and is collected via an electronic survey at the Baseline Visit (Visit 1) and Visit 14 (PT1). The primary purpose of MAIA-2 is to assess participants general interoceptive awareness (i.e., awareness of internal bodily sensations). The key domains are noticing, not-distracting, emotional awareness, self-regulation, body listening, and trusting.
Time frame: From enrollment to 8 weeks following enrollment
PROMIS - Global Health
The PROMIS - Global Health assesses general, health-related quality of life. This instrument has 10 questions in the key domains of physical health, mental health, social health, pain, and fatigue.
Time frame: From enrollment to 11 weeks following enrollment
PROMIS - Sleep
The PROMIS - Sleep questionnaire assesses quality of life relating to sleep. It has 10 questions.
Time frame: From enrollment to 8 weeks following enrollment
Patient Global Impression of Severity (PGI-S)
PGI-S is a single, global severity construct that assesses participants overall perception of cough severity. Using the single question of "How would you rate the overall severity of your cough?", participants will rate their perception of cough severity between 0-4 (0 representing "no cough" and 4 representing "very severe".
Time frame: From enrollment to 19 weeks following enrollment
Patient Global Impression of Change (PGI-C)
PGI-C is a single, global change construct used to assess participants overall perception of change following a treatment. It will be asked specifically in regard to treatment for chronic cough using the single question of "Since beginning treatment, how would you describe the overall change in your chronic cough?". Participants will rate their perception of change between 1-7 (1 representing "very much improved", 4 representing "no change", and 7 representing "very much worse".
Time frame: From enrollment to 19 weeks following enrollment
Study Specific Questions (3; 3-SSQ)
There are three, study specific questions that will be collected as a PROM at Baseline Visit (Visit 1), Visit 8, Visit 14/PT1, PT2, and PT3 to assess frequency of daily uncontrollable coughing, frequency of daily urinary incontinence, and frequency of daily urge-to-cough.
Time frame: From enrollment to 19 weeks following enrollment
Plan to share: Yes
Started Aug 2026 (actual). Primary completion is estimated for Jun 2029, 34 months after the start.
Of 25 phase 2 interventional studies under Chronic Cough, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 21. This study's planned 34 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Montana